biotech · Solid Tumors · Pancreatic Cancer · MREO
MEREO BIOPHARMA GROUP
Mereo BioPharma Group plc
MEREO BIOPHARMA GROUP is a biotech organization headquartered in LONDON, USA. It trades on NYSE under ticker MREO. Primary therapeutic focus areas include Solid Tumors, Pancreatic Cancer, Osteogenesis Imperfecta, Metasta
4TH FLOOR, ONE, LONDON, USA HQ
4 Employees
Public company Type
MREO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 4TH FLOOR, ONE, LONDON, USA
- Employees
- 4
- Programs
- 47
- Drugs
- 22
- Patents
- 18
Setrusumab
Phase 3 · mab · Osteogenesis Imperfecta
Setrusumab for Osteogenesis Imperfecta is a Phase 3 program (mab) at Mereo BioPharma Group plc with 2 ClinicalTrials.gov record(s).
Internal code UX143-CL301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Mereo BioPharma Group plc
- Phase
- Phase 3
- Modality
- mab
- Indication
- Osteogenesis Imperfecta
- Status
- active
- Trials
- 2